Gilead Sciences (NQ:GILD)

144.63 -0.11 (-0.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

78 79 Next >

3 Healthcare Stocks For Long-Term Growth And Dividends ↗

November 07, 2024

Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.

Via Talk Markets

Gilead’s Stock Surge: What’s Fueling the Momentum?

November 07, 2024

Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.

Via MarketBeat

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

November 07, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript ↗

November 06, 2024

GILD earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

November 06, 2024

Via Benzinga

Gilead Sciences's Earnings: A Preview ↗

November 05, 2024

Via Benzinga

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

October 31, 2024

Via ACCESSWIRE

Peering Into Gilead Sciences's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Gilead Sciences Announces Third Quarter 2024 Financial Results

November 06, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales ↗

November 06, 2024

The company also raised its earnings and sales guidance for the year.

Via Investor's Business Daily

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

November 05, 2024

From Gilead Sciences, Inc.

Via Business Wire

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗

October 21, 2024

Via Benzinga

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

October 17, 2024

Via Benzinga

Will GILEAD SCIENCES INC breakout? ↗

October 14, 2024

Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC.

Via Chartmill

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

October 22, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks ↗

October 21, 2024

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success...

Via Benzinga

Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 21, 2024

Via Benzinga

This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

October 21, 2024

Via Benzinga

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

October 19, 2024

From Gilead Sciences, Inc.

Via Business Wire

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗

October 18, 2024

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...

Via Benzinga

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 17, 2024

Via Benzinga

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

October 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

October 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biotech Stocks Poised For Another Big Move In Q4 ↗

October 07, 2024

The healthcare sector can be a safe haven if volatility increases.

Via Talk Markets

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

October 07, 2024

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.